Researchers Identify Predictors of Pulmonary Hypertension Among Patients with MPNs
Although the association of pulmonary hypertension (PH) and certain myeloproliferative neoplasms (MPNs) is recognized, the true prevalence is poorly understood. A study published in the European Journal of Haematology sought to better understand the prevalence of PH among patients with Philadelphia-chromosome negative MPNs, such as polycythemia vera (PV), essential thrombocytopenia (ET), and myelofibrosis (MF).
The survival for patients with PH is generally short at a median of just 2.8 years, and MPN-associated PH “has a similarly short survival.”
“Literature concerning PH in MPNs is relatively scarce, and although the prevalence is considered high, accurate estimates are lacking ...